In preclinical studies, RMC-7977 led to the regression of KRAS-mutant tumors and showed substantial efficacy in tumor models with KRAS exon 12 alterations.75 Recently, RMC-7977 has been assessed in patients with KRAS-mutant solid tumors (NCT05379985). This evidence concerns the gene KRAS and neoplasm.